About this item:

284 Views | 830 Downloads

Author Notes:

Correspondence: David P Holland, Box 102359 DUMC, Durham, NC 27710, USA, Tel +1 919 613 5160, Fax +1 919 684 8902, Email: david.pholland@duke.edu

The authors report no conflicts of interest in this work.



  • interferon-gamma release assay
  • isoniazid
  • rifampin
  • rifapentine
  • tuberculin skin test

Current management options for latent tuberculosis: A review


Journal Title:

Infection and Drug Resistance


Volume 5, Number 1


, Pages 163-173

Type of Work:

Article | Final Publisher PDF


Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

Copyright information:

© 2012 Norton and Holland, publisher and licensee Dove Medical Press Ltd.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Creative Commons License

Export to EndNote